^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    SEZ6-targeted antibody-drug conjugate

    Related drugs:
    22d
    Expanded Access to ABBV-706 (clinicaltrials.gov)
    P=N/A, N=0, Available, AbbVie
    New trial
    |
    ABBV-706
    29d
    SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=180, Recruiting, AbbVie | Trial completion date: May 2029 --> Sep 2031
    Trial completion date • Adverse events
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • Zepzelca (lurbinectedin) • ABBV-706
    1m
    SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=180, Recruiting, AbbVie | Trial completion date: Sep 2031 --> May 2029
    Trial completion date • Adverse events
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • Zepzelca (lurbinectedin) • ABBV-706
    1m
    SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=180, Recruiting, AbbVie | Not yet recruiting --> Recruiting | Phase classification: P2/3 --> P2
    Enrollment open • Phase classification • Adverse events
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • Zepzelca (lurbinectedin) • ABBV-706
    2ms
    SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2/3, N=180, Not yet recruiting, AbbVie | Trial completion date: May 2029 --> Sep 2031
    Trial completion date • Adverse events
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • Zepzelca (lurbinectedin) • ABBV-706
    3ms
    SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2/3, N=180, Not yet recruiting, AbbVie | N=730 --> 180 | Trial completion date: Sep 2031 --> May 2029 | Trial primary completion date: Sep 2031 --> May 2029
    Enrollment change • Trial completion date • Trial primary completion date • Adverse events
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • Zepzelca (lurbinectedin) • ABBV-706
    3ms
    M23-385: Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=288, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting
    Enrollment closed • Adverse events • First-in-human
    |
    EGFR (Epidermal growth factor receptor) • SEZ6 (Seizure Related 6 Homolog)
    |
    EGFR mutation • IDH wild-type
    |
    cisplatin • carboplatin • budigalimab (ABBV-181) • ABBV-706
    5ms
    SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2/3, N=730, Not yet recruiting, AbbVie
    New P2/3 trial • Adverse events
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • Zepzelca (lurbinectedin) • ABBV-706
    5ms
    M23-385: Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=350, Recruiting, AbbVie | Trial completion date: Nov 2027 --> Jun 2026 | Trial primary completion date: Nov 2027 --> Jun 2026
    Trial completion date • Trial primary completion date • Adverse events
    |
    EGFR (Epidermal growth factor receptor) • SEZ6 (Seizure Related 6 Homolog)
    |
    EGFR mutation • IDH wild-type
    |
    cisplatin • carboplatin • budigalimab (ABBV-181) • ABBV-706
    9ms
    Phase I Study of HS-20108 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=502, Not yet recruiting, Hansoh BioMedical R&D Company
    New P1 trial
    11ms
    M23-385: Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=350, Recruiting, AbbVie | Trial completion date: May 2027 --> Nov 2027 | Trial primary completion date: Oct 2025 --> Nov 2027
    Trial completion date • Trial primary completion date • Adverse events
    |
    EGFR (Epidermal growth factor receptor) • SEZ6 (Seizure Related 6 Homolog)
    |
    EGFR mutation • IDH wild-type
    |
    cisplatin • carboplatin • budigalimab (ABBV-181) • ABBV-706
    over1year
    Detection of SEZ6, a therapeutic target, in medullary thyroid carcinoma. (PubMed, J Clin Endocrinol Metab)
    SEZ6 may serve as a novel biomarker for MTCs. Although SEZ6 lacks any prognostic values in MTC, its positivity in 91% to 93% of MTCs, including MTCs without RET and RAS mutations, renders SEZ6-targetted antibody-drug conjugate therapy a promising targeted therapy for MTCs.
    Journal
    |
    SEZ6 (Seizure Related 6 Homolog)
    |
    RAS mutation • RET mutation • SEZ6 expression
    |
    ABBV-011